Klaus Geissler, MD; Christa Forstinger, MD; Peter Kalhs, MD; Paul Knöbl, MD; Peter Kier, MD; Paul Kyrle, MD; Klaus Lechner, MD
Some patients with aplastic anemia show temporary improvements in hematopoiesis after monotherapy with hematopoietic growth factors (1-3), but those with severe cases rarely respond (4). Inadequate response in these patients is thought to be caused by a profound deficiency of hematopoietic progenitors (5). We recently reported that interleukin-3 effectively expands the pool of hematopoietic progenitors in primates, suggesting that this molecule may be used therapeutically to make hematopoiesis more responsive to late-acting cytokines (6). Pretreatment with interleukin-3 has been shown to potentiate the effects of granulocyte-macrophage colony-stimulating factor on myelopoiesis (7), of erythropoietin on erythropoiesis (8), and of interleukin-6 on
Geissler K, Forstinger C, Kalhs P, Knöbl P, Kier P, Kyrle P, et al. Effect of Interleukin-3 on Responsiveness to Granulocyte-Colony-stimulating Factor in Severe Aplastic Anemia. Ann Intern Med. ;117:223–225. doi: 10.7326/0003-4819-117-3-223
Download citation file:
Published: Ann Intern Med. 1992;117(3):223-225.
Hematology/Oncology, Red Cell Disorders.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use